Xin Lang Cai Jing·2025-08-28 06:25Group 1 - The core viewpoint of the report indicates that Fosun Pharma (02196.HK) demonstrated resilience in its Q2 performance, with a 7.2% quarter-on-quarter increase in revenue and a 22.5% quarter-on-quarter increase in net profit, primarily driven by strong sales of innovative products [1] - The new employee stock ownership plan is expected to provide greater visibility for growth and alleviate market concerns following leadership changes, with the plan's conditions linked to achieving a 20% compound annual growth rate (CAGR) for both innovative drug sales and net profit from this year until 2027 [1] - The company successfully completed two licensing transactions for independently developed molecules, which further supports its growth strategy [1] Group 2 - The report includes an upward revision of Fosun Pharma's core profit forecasts for the years 2023 to 2027, with adjustments ranging from approximately 13% to 21% [1] - The target price for the H-shares has been raised from HKD 15.6 to HKD 29.6, while maintaining an outperform rating [1]